Stockreport
Concert Pharmaceuticals Selected for Late-Breaking Oral Presentation of CTP-543 Phase 2 Data in Alopecia Areata at 2019 AAD Annual Meeting
Last concert pharmaceuticals, inc earnings: 11/1 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations: ir.concertpharma.com/investor-relations
PDF
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that interim clinical data from its CTP-543 Phase 2 trial in alopecia areata has been selected for an oral presentation at the Late-Breaking Research Program during the American Academy of Dermatology (AAD) Annual Meeting being held March 1 - 5, 2019 in Washington, D.C. The details of the presentation are as follows: Title: JAK Inhibitor CTP-543 Achieves Primary Endpoint in Phase 2 Trial in Alopecia Areata Date and Time: Saturday, March 2, 2019, 1:00 - 4:00 p.m. Session: S034: Late-Breaking Research: Clinical Trials Room: Ballroom A Abstract Number: 11291 About CTP-543 CTP-543 was discovered by applying Concert's deuterium chemistry technology to modify ruxolitinib, a drug which inhibits Janus kinases 1
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | CNCE | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
CNCE alerts
CNCE alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CNCE alerts
High impacting Concert Pharmaceuticals, Inc news events
Weekly update
A roundup of the hottest topics
CNCE
NEWS
NEWS
- Concert Pharmaceuticals Initiates Phase 1 Single-Ascending Dose Trial of CTP-692 as an Adjunctive Treatment for Schizophrenia[Business Wire]
- Concert Pharmaceuticals Completes Enrollment of 12 mg Cohort in Phase 2a Trial of CTP-543 in Alopecia Areata[Business Wire]
- Concert Pharmaceuticals Inc (NASDAQ: CNCE) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating.[MarketBeat]
- Concert Pharmaceuticals Inc (NASDAQ: CNCE) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating.[MarketBeat]
- Concert Pharmaceuticals initiates phase 1 program of CTP-692 for the treatment of schizophrenia [Seeking Alpha][Seeking Alpha]
- More
CNCE
SEC Filings
SEC Filings
- 2/14/19 - Form SC
- 2/7/19 - Form SC
- 2/7/19 - Form SC
- CNCE's page on the SEC website
- More